Skip to menu Skip to content Skip to footer
Dr Andy Moore
Dr

Andy Moore

Email: 

Overview

Background

Associate Professor Andy Moore is a Paediatric Oncologist and Director of Research at Children's Health Queensland Hospital & Health Service (CHQ). He is also Director of the Queensland Children's Tumour Bank, a unique resource located on the Queensland Children's Hospital precinct, facilitating local, national and international collaborative research across all childhood cancer types and supporting enrolment of children on clinical trials. A/Prof. Moore's clinical and research interests focus on childhood leukaemia, particularly acute myeloid leukaemia (AML), an aggressive form of leukaemia with a poor prognosis. He also holds a number of leadership and advisory roles, including Deputy Chair of the Australian & New Zealand Childrens Haematology / Oncology Group (ANZCHOG).

Availability

Dr Andy Moore is:
Not available for supervision
Media expert

Qualifications

  • Bachelor of Medicine and Surgery and Medical Science, The University of Queensland
  • Doctor of Philosophy, University College London

Research interests

  • Acute Myeloid Leukaemia

  • Leukaemia

  • Blood Cancers

  • Paediatric Oncology

  • Childhood Cancer

  • Biobanking

Works

Search Professor Andy Moore’s works on UQ eSpace

94 works between 2007 and 2024

81 - 94 of 94 works

2012

Journal Article

A stable-isotope HPLC-MS/MS method to simplify storage of human whole blood samples for glutathione assay

Norris, R. L. G., Paul, M., George, R., Moore, A., Pinkerton, R., Haywood, A. and Charles, B. (2012). A stable-isotope HPLC-MS/MS method to simplify storage of human whole blood samples for glutathione assay. Journal of Chromatography B, 898, 136-140. doi: 10.1016/j.jchromb.2012.04.003

A stable-isotope HPLC-MS/MS method to simplify storage of human whole blood samples for glutathione assay

2011

Journal Article

Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited-sampling, population modelling approach

Moore, Andrew S., Norris, Ross, Price, Gareth, Nguyen, Thu, Ming, Ni, George, Rani, van Breda, Karin, Duley, John, Charles, Bruce and Pinkerton, Ross (2011). Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited-sampling, population modelling approach. Journal of Paediatric and Child Health, 47 (12), 875-882. doi: 10.1111/j.1440-1754.2011.02103.x

Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited-sampling, population modelling approach

2011

Journal Article

Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia

Podesta, Jennifer E., Sugar, Richard, Squires, Matt, Linardopoulos, Spiros, Pearson, Andrew D. J. and Moore, Andrew S. (2011). Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia. Leukemia Research, 35 (9), 1273-1275. doi: 10.1016/j.leukres.2011.05.022

Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia

2011

Conference Publication

Blood collection technique for pharmacokinetic studies of doxorubicin in paediatric patients

Lobb, M., Norris, R. L. G., Charles, B., Gilshenan, K., Moore, A. and Pinkerton, R. (2011). Blood collection technique for pharmacokinetic studies of doxorubicin in paediatric patients. 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Stuttgart, Germany, 2-6 October, 2011. Philadelphia PA, United States: Lippincott Wiliams & Wilkins. doi: 10.1097/01.ftd.0000400651.94145.ba

Blood collection technique for pharmacokinetic studies of doxorubicin in paediatric patients

2011

Conference Publication

Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736

Moore, AS, Faisal, A, Bavetsias, V, de Castro, DG, Sun, CB, Atrash, B, Valenti, M, Brandon, AD, Avery, S, Pearson, ADJ, Workman, P, Blagg, J, Raynaud, FI, Eccles, SA and Linardopoulos, S (2011). Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego CA, DEC 10-13, 2011.

Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736

2010

Journal Article

Aurora kinase inhibitors: Novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias

Moore, A. S., Blagg, J., Linardopoulos, S. and Pearson, A. D. J. (2010). Aurora kinase inhibitors: Novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia, 24 (4), 671-678. doi: 10.1038/leu.2010.15

Aurora kinase inhibitors: Novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias

2010

Conference Publication

Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 kinases by AT9283 In Children and Adolescents with Leukaemia.

Podesta, JE, Griffin, MJ, Sugar, R, Squires, MS, Boddy, A, Linardopoulos, S, Pearson, ADJ and Moore, AS (2010). Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 kinases by AT9283 In Children and Adolescents with Leukaemia.. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Orlando FL, DEC 04-07, 2010.

Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 kinases by AT9283 In Children and Adolescents with Leukaemia.

2010

Conference Publication

Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo

Moore, AS, Faisal, A, Bavetsias, V, Sun, CB, Atrash, B, Valenti, M, Brandon, AD, Avery, S, Raynaud, FI, Workman, P, Pearson, ADJ, Blagg, J, Eccles, SA and Linardopoulos, S (2010). Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Orlando FL, DEC 04-07, 2010.

Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo

2009

Journal Article

Vincristine: Can its therapeutic index be enhanced?

Moore, Andrew and Pinkerton, Ross (2009). Vincristine: Can its therapeutic index be enhanced?. Pediatric Blood and Cancer, 53 (7), 1180-1187. doi: 10.1002/pbc.22161

Vincristine: Can its therapeutic index be enhanced?

2009

Journal Article

Localised peripheral primitive neuroectodermal tumour (PNET) of the conjunctiva

Moore, Andrew S., Wilson, Peter G., McKelvie, Penny, La Nauze, Jamie and Hirst, Lawrence W. (2009). Localised peripheral primitive neuroectodermal tumour (PNET) of the conjunctiva. Pediatric Blood and Cancer, 53 (4), 669-671. doi: 10.1002/pbc.22062

Localised peripheral primitive neuroectodermal tumour (PNET) of the conjunctiva

2009

Journal Article

Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group

Moore, A.S., Shaw, P.J., Hallahan, A.R., Carter, T, Kilo, T, Nivison-Smith, I, O'Brien, T.A., Tapp, H, Teague, L, Wilson, S.R. and Tiedemann, K (2009). Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group. Medical Journal of Australia, 190 (3), 121-125.

Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group

2008

Conference Publication

Use of etanercept in children following haematopoietic stem cell transplantation: a single institution experience

Moore, A.S. and Hallahan, A.R. (2008). Use of etanercept in children following haematopoietic stem cell transplantation: a single institution experience. 48th Annual Scientific Meeting of the British Society for Haematology, Glasgow, Scotland, 7-9 April 2008. United Kingdom: Wiley-Blackwell Publishing Ltd.. doi: 10.1111/j.1365-2141.2008.07061.x

Use of etanercept in children following haematopoietic stem cell transplantation: a single institution experience

2007

Journal Article

Re: Hyponatraemia and seizures in oncology patients associated with hypotonic intravenous fluids

Moore, A, Suppiah, R and Weier, S (2007). Re: Hyponatraemia and seizures in oncology patients associated with hypotonic intravenous fluids. Journal of Paediatrics And Child Health, 43 (5), 415-416. doi: 10.1111/j.1440-1754.2007.01094.x

Re: Hyponatraemia and seizures in oncology patients associated with hypotonic intravenous fluids

2007

Conference Publication

Does myelosuppression during consolidation or high-dose methotrexate clearance correlate with tolerance of initial maintenance therapy in childhood acute lymphoblastic leukaemia?

Moore, Andrew, Charles, Bruce, Wilkinson, Catherine, Weier, Steven and Pinkerton, Ross (2007). Does myelosuppression during consolidation or high-dose methotrexate clearance correlate with tolerance of initial maintenance therapy in childhood acute lymphoblastic leukaemia?. 39th Annual Conference of the International Society of Paediatric Oncology SIOP 2007, Mumbai, India, 31 October-3 November 2007. Hoboken: Wiley-Liss, Inc. doi: 10.1002/pbc.21342

Does myelosuppression during consolidation or high-dose methotrexate clearance correlate with tolerance of initial maintenance therapy in childhood acute lymphoblastic leukaemia?

Supervision

Availability

Dr Andy Moore is:
Not available for supervision

Supervision history

Completed supervision

Media

Enquiries

Contact Dr Andy Moore directly for media enquiries about:

  • Childhood Cancer
  • Childhood Leukaemia

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au